Collaborators

Collaborating Centers at Emory

The Emory+Children’s Cystic Fibrosis Center of Excellence

At the Cystic Fibrosis Center of Excellence, researchers and clinicians are working together to provide the best in clinical care and transform the approach to this deadly disease.  A joint collaborative team of investigators from Emory and Georgia Tech working together via the Center for CF and Airways Disease Research (CF-AIR), a component of the Center of Excellence, bring new therapies, drugs, and devices to patients to improve the quality of their lives. The Center is also involved in training the next generation of researchers and in education and outreach to the community.

Emory Vaccine Center

The Emory Vaccine Center (EVC) is a world leader in the discovery, development and clinical analysis of safe, effective and affordable vaccines. The EVC is making fundamental advances in immunology and vaccine research to search for life saving cures against the world’s most threatening diseases plaguing millions of individuals around the globe.

The Hope Clinic of the Emory Vaccine Center serves as the clinical arm, directing all current on-site clinical vaccine trials. As one of eight participating national sites in the NIAID’s prestigious Vaccine Trials Evaluation Units (VTEUs), the Clinic plays a vital role in advancing the most promising pre-clinical vaccine research into human clinical trials.

Children’s Healthcare of Atlanta

Children’s Healthcare of Atlanta (CHOA), a national leader and the largest pediatric clinical system in the country, is consistently ranked among the top pediatric hospital systems in the country (e.g., by U.S. News & World Report). CHOA works in partnership with Emory University, enhancing research infrastructure and bringing together multidisciplinary groups to achieve excellence in clinical and basic research on topics important to child health. This structure supports robust research centers including the Children's Center for Childhood Infections and Vaccines and the Center for Drug Discovery.

Local Collaborators

Georgia Emerging Infections Program

The Georgia Emerging Infections Program is a collaborative project with the Georgia Department of Health, Emory University, and the CDC that conducts active surveillance and initiates research studies related to food-borne and invasive bacterial pathogens and other emerging infectious diseases.

Georgia Department of Public Health Laboratory

The Georgia Department of Public Health Laboratory (GPHL) Program is improving the health status of Georgians by providing accurate, timely and confidential clinical and non-clinical laboratory testing in support of Department of Public Health programs, activities and initiatives. Emory ARC faculty work with the GPHL to use next generation sequence analysis to study antimicrobial resistance.

Georgia Institute of Technology

The SimTigrate Design Lab within the Georgia Tech College of Architecture is an interdisciplinary research effort dedicated to driving healthcare innovation through the integration of evidence-based design and simulation. The SimTigrate team seeks to transform healthcare, predict and optimize outcomes and decrease cost. Emory ARC faculty work with the SimTigrate team to investigate the link between the built (physical) environment in the hospital and healthcare-associated infections, particularly those caused by multi-drug resistant bacteria.

Mercer University College of Pharmacy

Mercer’s Center for Pharmacometrics quantifies drug, disease and clinical trial data to inform drug development, regulatory and dosage decisions that ultimately appear on prescription labels. Emory ARC faculty collaborate with the Center for Pharmacometrics researchers to develop new approaches to optimally dose antibiotics.

Morehouse School of Medicine

The Morehouse School of Medicine is dedicated to improving the health and well-being of individuals and communities; increasing the diversity of the health professional and scientific workforce; and addressing primary healthcare needs through programs in education, research, and service. Morehouse, Emory ARC, and Emory/Georgia Tech Coulter Department of Biomedical Engineering faculty study novel devices to prevent central line-associated bloodstream infections.

Georgia Aquarium

The Georgia Aquarium houses over 100,000 animals, representing 500 species. Emory ARC researchers collaborate with the Georgia Aquarium to study genomics, infectious diseases, and antibiotic resistance in marine mammals.

Global Collaborators

Queensland Emory Development Alliance

The Queensland Emory Development (QED) Alliance includes Emory University, the Queensland Institute of Medical Research (QIMR) and the University of Queensland (UQ). The alliance aims to accelerate the development of new drugs and vaccines for infectious diseases, including those caused by antibiotic-resistant bacteria.

ICGEB-Emory Vaccine Center

The ICGEB-Emory Vaccine Center is a joint venture of the Emory Vaccine Center and the New Delhi-based International Center for Genetic Engineering and Biotechnology. The primary purpose of the Center is to improve the control of infectious diseases around the world with a special emphasis on those diseases that disproportionately affect vulnerable populations in the developing world. To accomplish its goals, the Center conducts basic and translational research to discover effective vaccines for numerous infectious diseases including highly antibiotic-resistant tuberculosis.

Emory/Republic of Georgia Collaboration

Emory University has a long-standing collaboration with multiple institutions in the Republic of Georgia including the National Center for Tuberculosis and Lung Diseases (NCTLD), National Center for Disease Control (NCDC), and the Infectious Diseases, AIDS, and Clinical Immunology Research Center. The relationship is currently supported by NIH Fogarty and NIAID funding and focuses on research training and clinical and translational research. The main focus of research is on multi- and extensively drug-resistant tuberculosis with ongoing projects evaluating the performance and impact of new diagnostics, clinical outcomes, genetic mutations associated with drug resistance, and pharmacology of second-line and newly introduced drugs.